louisiana semaglutide stomach paralysis legal team blockage digestive attorney in gastric intestinal obstruction lawyer louisiana semaglutide gastrointestinal obstruction law firm louisiana semaglutide gastric intestinal obstruction Semaglutide Lawsuit-150cent Ozempic glp-1 diarrhea law office in

More studies are ongoing to understand further the full extent of semaglutide's cardiovascular benefits and potential uses in other cardiovascular-risk populations

Some prescribers step the dose down rather than stopping outright, smoothing the return of appetite further, and evidence across the drug class suggests some weight regain is common after stopping, so agreeing in advance what would prompt a return to treatment removes the sting from that possibility

Samozejm

A major real-world study published in early 2026 led by researchers at Johns Hopkins Bloomberg School of Public Health and analysing electronic health records from approximately 175,000 people with T1D in the US found that those taking GLP-1 drugs had a roughly 15% lower five-year risk of major cardiovascular events and a 19% lower risk of end-stage kidney disease, without any increase in hospitalisation for DKA or severe hypoglycemia